Original Article

Evaluation of the Histopathological Features of Early-stage Invasive Ductal Breast Carcinoma by 18Fluoride-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography

10.4274/mirt.galenos.2021.25582

  • Mustafa Erol
  • Hasan Önner
  • Meryem İlkay Eren Karanis

Received Date: 25.12.2020 Accepted Date: 06.04.2021 Mol Imaging Radionucl Ther 2021;30(3):129-136 PMID: 34658227

Objectives:

This study investigates the relationship between 18fluoride-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) parameters and histopathological features in patients with early-stage invasive ductal breast carcinoma (IDBC).

Methods:

Patients with early-stage IDBC who underwent 18F-FDG PET/CT scan for staging were included in this retrospective study. The status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2, Ki-67 proliferative index, and grades of tumors were recorded. The conventional metabolic parameters [maximum standard uptake value (SUVmax) and average standard uptake value] and volume-based parameters [metabolic tumor volume (MTV) and total lesion glycolysis] of the primary tumor were obtained from the 18F-FDG PET/CT images. The associations and correlations between the 18F-FDG PET/CT parameters and histopathological features were assessed.

Results:

One hundred forty-three patients were included. 18F-FDG PET/CT parameters, other than MTV, were significantly associated with the ER and PR status and Ki-67 index, while T-staging was significantly associated with all 18F-FDG PET/CT parameters. In the axillary lymph node (ALN) involvement, no significant difference was found in the 18F-FDG PET/CT parameters. In terms of the pathological stage, a significant difference was found in all 18F-FDG PET/CT parameters. 18F-FDG PET/CT parameters, other than MTV, were significantly higher in non-luminal breast tumors than luminal tumors and in high-grade tumors than low-grade ones. Triple-negative tumors had the highest 18F-FDG PET/CT parameter, but the difference was insignificant for MTV. The SUVmax had the strongest correlation with Ki-67 proliferative index.

Conclusion:

Tumors with aggressive histopathological features had higher 18F-FDG PET/CT parameter values. This study suggests that 18F-FDG PET/CT may provide prognostic information in patients with early-stage IDBC.

Keywords: Breast cancer, metabolic tumor volume, total lesion glycolysis, 18fluoride-fluorodeoxyglucose, positron emission tomography/computed tomography

Introduction

Breast cancer (BC) is the most widely diagnosed form of cancer and the second cause of cancer-related death in women (1). The most common pathological subtype is invasive ductal breast carcinoma (IDBC), which is associated with different prognostic behaviors concerning molecular subtypes (2). The size and grade of tumors, hormonal receptor status, human epidermal growth factor receptor-2 (HER-2) expression, Ki-67 proliferative index, axillary lymph node (ALN) involvement, and distant metastasis are important for the prognosis and treatment of IDBC (3,4).

18Fluoride-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) has been widely used for the staging, restaging, assessment of treatment response, and prediction of prognosis in BC (5). Several studies have previously evaluated the relationship between the maximum standard uptake value (SUVmax) and clinicopathological factors in BC (6,7,8,9,10,11), while the metabolic tumor volume (MTV) or total lesion glycolysis (TLG), called volume-based PET parameters, shows the total tumor burden and tumor metabolism. The prognostic value of these parameters was significantly associated with BC subtypes and prognosis in many studies (12,13,14,15,16,17).

This study aimed to evaluate the relationship between the 18F-FDG PET/CT parameters [SUVmax, average standard uptake value (SUVavg), MTV, and TLG] and histopathological features (pathologic T size, pathological stage, ALN involvement, hormone receptor expressions, HER-2 receptor expression, Ki-67 proliferative index, and molecular subtypes) in IDBC.


Materials and Methods

The Local Ethics Committee of KTO Karatay University Faculty of Medicine approved this study under the decision number: 2020/10. Written informed consent was obtained from all patients. The data of patients with histopathologically documented and surgically excised IDBC, who underwent a preoperative 18F-FDG PET/CT between July 2013 and December 2019, were analyzed. Patients with the following features were excluded from the study: Multifocal or multicentric tumors; bilateral breast tumors; chest wall, surrounding muscle, or skin tissue involvement; distant metastasis; missing clinical data; those with a history of any therapeutic intervention before surgery (e.g., chemotherapy, radiotherapy, and hormone therapy). Moreover, in this study, the largest diameter of the evaluated lesions required to be larger than 10 mm to decrease the partial volume effect.


Imaging and Analysis of 18F-FDG PET/CT

Before the 18F-FDG injection, the patients were fasted for at least six hours to ensure that the blood glucose levels were below 150 mg/dL. The scan was performed 60 min after the intravenous injection. The region of interest (ROI) around the primary tumor was drawn by manual adjustment to exclude structures showing physiological 18F-FDG uptake around the tumor. The tumor was completely covered in three planes. SUVmax was obtained by manually drawing the ROI from the slice with the highest uptake of 18F-FDG in the primary tumor. MTV was obtained using a 42% threshold of SUVmax. TLG was calculated by multiplying SUVavg by MTV.


Histopathological Analysis and Molecular Subtypes

Patients included in this study underwent surgery or ALN dissection. The pathological data of the tumors, such as size, grade, pathological stage, and other prognostic parameters, were obtained from the records. The tumor has been graded according to the Bloom-Richardson grading system updated by Elston and Ellis (18). The pathological prognostic staging was performed according to the eighth edition of the American Joint Committee on Cancer’s Staging Manual (19). The status of the estrogen receptor (ER), progesterone receptor (PR), and HER-2 expression and the Ki-67 proliferative index were evaluated immunohistochemically. The fluorescence in situ hybridization method was used to confirm the presence of HER-2 expression, when the scores were 2+ (20). The molecular subtypes of the ER, PR, and HER-2 expression status were determined. The proliferative index was considered high when the Ki-67 was ≥14% and low when it was <14%. The subjects were classified according to the molecular subtypes as recommended in the 12th International Breast Conference (2). The molecular subtypes were divided into two groups: Luminal (luminal A, luminal B HER-2-negative, and luminal B HER-2-positive subtypes) and non-luminal [HER-2-positive and triple-negative (TN) subtypes].


Statistical Analysis

The statistical analyses were performed using IBM SPSS Statistics for Windows (ver. 21, IBM Corp., Armonk, NY). The normality of the distribution of the continuous data was evaluated. The continuous data were expressed as medians or mean ± standard deviations, where appropriate. The categorical data were shown as frequencies and percentages. For comparing continuous data, non-parametric tests were used. The relationship between the continuous data was evaluated using a Spearman correlation test. A p value less than 0.05 was considered statistically significant.


Results

One hundred forty-three female patients with IDBC and a mean age of 52.43±11.79 years (range: 29-81 years) were included. Table 1 shows the characteristics of the patients. Table 2 shows the relationship between the histopathological features and 18F-FDG PET/CT parameters.

Fifty-nine (41.3%) tumors were stage T1c, and 84 (58.7%) tumors were stage T2. The median values of all 18F-FDG PET/CT parameters were higher in the T2 group than the T1c group (p<0.001 for all comparisons).

All 18F-FDG PET/CT parameters were almost similar across ALN states. The SUVmax, SUVavg, and TLG were higher in high-grade tumors (p<0.001 for all comparisons). Moreover, high-grade tumors had higher MTV, but the difference was insignificant.

The SUVmax, TLG, and SUVavg were higher in hormone-receptor-negative tumors compared with the positive ones. The MTV was also higher in hormone-receptor-negative tumors compared with the positive ones, but the differences were insignificant. HER-2-positive tumors had higher SUVavg and SUVmax than the negative ones (p=0.046 and p=0.04, respectively). The TLG and MTV were higher in HER-2-positive tumors compared with the negative ones, but the differences were insignificant.

Figure 1 shows the transaxial slice of PET/CT images of a patient with IDBC (histologic grade 3; ER-positive, PR-positive, and HER-2-positive).

Luminal A was found in 33 patients (23.1%); luminal B HER-2-negative, 61 patients (42.7%); luminal B HER-2-positive, 28 patients (19.6%); HER-2-positive, 10 patients (7.0%); TN, 11 patients (7.7%). The SUVmax, SUVavg, and TLG were different among the five molecular subtypes (p<0.001, p<0.001, and p=0.010, respectively). Although MTV varied among the molecular subtypes, the difference was insignificant. All 18F-FDG PET/CT parameters were the highest in TN groups in terms of the molecular subtypes. In the post-hoc analysis, the luminal A group had a significantly lower SUVmax (p=0.026 and p<0.001, respectively) and SUVavg (p=0.016 and p<0.001, respectively) than the HER-2-positive and TN groups. The luminal B HER-2-negative group had a significantly lower SUVmax (p=0.006) and SUVavg (p=0.007) than the TN group. TLG was significantly lower in the luminal A group compared with the TN group (p=0.015).

Among the 18F-FDG PET/CT parameters, TLG had the strongest correlation with the tumor’s diameter (r=0.679; p<0.001). Moreover, SUVavg had a modest correlation with Ki-67 (r=0.472; p<0.001). The group with Ki-67 ≥14% had a significantly higher SUVavg, SUVmax, and TLG compared with that with Ki-67 <14% (p<0.001, p<0.001, and p=0.002, respectively). The MTV was higher in the group with Ki-67 ≥14% compared with that with Ki-67 <14%, but the difference was statistically insignificant.

There was a difference in the volumetric parameters (MTV and TLG) in the pathological stage (p<0.001 for both comparisons). Other PET parameters also varied significantly (SUVmax and SUVavg; p=0.013 and p=0.028, respectively). In the post-hoc analysis, stage-I and stage-II tumors showed differences in terms of SUVmax (p=0.01), SUVavg (p=0.026), MTV (p<0.001), and TLG (p<0.001), and stage-I and stage-III tumors showed differences in terms of MTV (p=0.008) and TLG (p=0.001).

Table 3 shows the comparison of the area-under-the-curve (AUC) values of 18F-FDG PET/CT parameters for the histopathological. The AUC values were similar in all tested features except for MTV. Of note, the AUC of SUVavg was the largest for ER and PR status, Ki-67 index, and molecular group. Considering the HER-2 status, TLG had the largest AUC.


Discussion

IDBC is a heterogeneous group of tumors (21). Several studies have reported a correlation between the parameters of 18F-FDG PET/CT and the histopathological features of BC (12,22,23,24). However, most of them evaluated different histological subtypes of BC and reported highly variable results. This study showed that tumors with aggressive histopathological features are associated with high 18F-FDG PET/CT parameters in IDBC.

An independent prognostic factor for BC is the tumor’s size. Moreover, poor histopathological differentiation and larger tumor size are related to an increased metastasis risk in BC (25). While some studies reported the correlation between the tumor’s size and 18F-FDG PET/CT parameters (9,23,26,27,28), others did not report such an association (8,10,29). In this study, the T-stage groups were associated with all 18F-FDG PET/CT parameters. Our patient population was predominantly composed of individuals with pathological T2-stage tumors, and there were no T3 tumors in this series.

Studies showed that the negative ER status was associated with higher 18F-FDG PET/CT parameters (12,24,26). In line with these studies, we found significantly higher 18F-FDG PET/CT parameters in ER-negative patients than ER-positive patients, but the difference was statistically insignificant for MTV. According to the studies by Kajáry et al. (12) and Groheux et al. (24), a negative PR status was associated with higher SUVmax, MTV, and TLG. Conversely, according to the study by Kaida et al. (23), there was no association between PR status and any volumetric parameters (MTV and TLG). In the present study, there was a significant association between the ER or PR status and the 18F-FDG PET/CT parameters, except for MTV. Some studies (12,30) have reported significant associations between HER-2 status and 18F-FDG PET/CT parameters, but others did not report such an association (24,29). All 18F-FDG PET/CT parameters were higher in HER-2-positive tumors than the negative ones, but significant associations were observed only for SUVmax and SUVavg in the present study. A higher histological grade is associated with aggressive behavior (24). Several studies have demonstrated a significant relationship between the histological grade and 18F-FDG PET/CT parameters (9,10,12,26,31,32,33). Similarly, in the present study, there was a significant association between tumor’s grade and all 18F-FDG PET/CT parameters, except for MTV. Several studies have demonstrated a positive correlation between the Ki-67 index levels and 18F-FDG PET/CT parameters (9,26,29,32). Similarly, in our study, a positive correlation was observed between the Ki-67 levels and SUVmax, SUVavg, and TLG. When the patients were grouped for their Ki-67 levels, the higher-level group had a significantly higher SUVmax, SUVavg, and TLG. Our results showed that, among the 18F-FDG PET/CT parameters, SUVmax had the strongest correlation with Ki-67.

Studies have reported that molecular subtypes are associated with a variable prognosis, for example, the worst for TN and HER-2-positive and the best for luminal A (12,26,34). Concerning the molecular subtypes, Kajáry et al. (12), Groheux et al. (24), and Önner et al. (26) reported significant associations with SUVmax, SUVavg, and TLG. Similarly, in our study, there was a significant relationship between the molecular subtypes and 18F-FDG PET/CT parameters, except for MTV. In the luminal A subtype, cellular proliferation genes are expressed at low levels. Conversely, the HER-2 gene promotes both cancer growth and progression, and the rates of recurrence and mortality are higher in the HER-2-positive subtype (35). TN BC is the most aggressive subtype and is associated with a worse prognosis (36). In this study, the lowest SUVmax, SUVavg, and TLG were observed in the luminal A group, while the highest was in the TN group. In this line, Önner et al. (26) and Kajáry et al. (12) observed the lowest SUVmax, SUVavg, MTV, and TLG in the luminal A group and the highest SUVmax, MTV, and TLG in the TN group. In this study, SUVmax, SUVavg, and TLG were significantly higher in the non-luminal group. Regarding MTV, the median values of MTV were similar in both groups. Similarly, previous studies reported that 18F-FDG parameters were significantly higher in the non-luminal groups (12,24,26).

We performed receiver operating characteristic analyses to find which 18F-FDG PET/CT parameters reflected the pathological features better. The AUC values of SUVmax, SUVavg, and TLG were high in all pathological variables (ER, PR, and HER-2 status, Ki-67 index, and molecular subtypes). The largest AUC value was seen for SUVavg in terms of the ER and PR status, Ki-67 index, and molecular groups and for TLG in terms of the HER-2 status. This was incompatible with some recent studies (12,23). We think that these differences are due to different SUVmax threshold values used in MTV calculation. Kaida et al. (23) used a threshold of 50% of peak SUV within the lesions for calculating MTV and reported that TLG reflected the tumor metabolism with histopathological features better than SUVmax or MTV. However, in another study using 2.5 as the SUVmax threshold value in MTV calculation, a high AUC value could not be achieved with MTV. There is a lack of consensus on methods for calculating the volumetric parameters in the literature (12,23,24,26,37,38). In solid tumors such as BC, some authors recommend using 42% of tumor SUVmax as a threshold to represent the glycolytic activity (37,38). So, we used 42% as the threshold for the present study.


Study Limitations

The limitations of this study include being retrospective and having low patients in the groups. Moreover, we cannot predict the findings of this study in patients with advanced IDBC.


Conclusion

The findings of this study showed that tumors with aggressive histopathological features are associated with high 18F-FDG PET/CT parameters, and therefore, 18F-FDG PET/CT imaging can be used as an aid in predicting the prognosis in early-stage IDBC.


Ethics

Ethics Committee Approval: The Local Ethics Committee of KTO Karatay University Faculty of Medicine approved this study under the decision number: 2020/10.

Informed Consent: Written informed consent was obtained from all patients.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: M.İ.E.K., Concept: M.E., H.Ö., Design: M.E., H.Ö., Data Collection or Processing: M.E., H.Ö., M.İ.E.K., Analysis or Interpretation: M.E., Literature Search: M.E., Writing: M.E.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

Images

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34.
  2. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-1747.
  3. Banerjee M, George J, Song EY, Roy A, Hryniuk W. Tree-based model for breast cancer prognostication. J Clin Oncol 2004;22:2567-2575.
  4. Kwast AB, Voogd AC, Menke-Pluijmers MB, Linn SC, Sonke GS, Kiemeney LA, Siesling S. Prognostic factors for survival in metastatic breast cancer by hormone receptor status. Breast Cancer Res Treat 2014;145:503-511.
  5. Caresia Aroztegui AP, García Vicente AM, Alvarez Ruiz S, Delgado Bolton RC, Orcajo Rincon J, Garcia Garzon JR, de Arcocha Torres M, Garcia-Velloso MJ; Oncology Task Force of the Spanish Society of Nuclear Medicine and Molecular Imaging. 18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging. Tumour Biol 2017;39:1010428317728285.
  6. Song BI, Hong CM, Lee HJ, Kang S, Jeong SY, Kim HW, Chae YS, Park JY, Lee SW, Ahn BC, Lee J. Prognostic Value of Primary Tumor Uptake on F-18 FDG PET/CT in Patients with Invasive Ductal Breast Cancer. Nucl Med Mol Imaging 2011;45:117-124.
  7. Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 2006;98:267-274.
  8. Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F, Nathrath W, Schwaiger M. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001;42:9-16.
  9. Gil-Rendo A, Martínez-Regueira F, Zornoza G, García-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg 2009;96:166-170.
  10. Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, de Roquancourt A, Hamy AS, Cuvier C, Vercellino L, Hindié E. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 2011;38:426-435.
  11. Koo HR, Park JS, Kang KW, Cho N, Chang JM, Bae MS, Kim WH, Lee SH, Kim MY, Kim JY, Seo M, Moon WK. 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes. Eur Radiol 2014;24:610-618.
  12. Kajáry K, Tőkés T, Dank M, Kulka J, Szakáll S Jr, Lengyel Z. Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer. Nucl Med Commun 2015;36:28-37.
  13. Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC. Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT. Cancer 2015;121:3965-3974.
  14. Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, Kim H, Lee KH, Kim BT. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg 2013;257:364-370.
  15. Son SH, Lee SW, Jeong SY, Song BI, Chae YS, Ahn BC, Lee J. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis. AJR Am J Roentgenol 2015;205:878-885.
  16. Ulaner GA, Eaton A, Morris PG, Lilienstein J, Jhaveri K, Patil S, Fazio M, Larson S, Hudis CA, Jochelson MS. Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. Cancer Med 2013;2:725-733.
  17. Kim J, Yoo SW, Kang SR, Cho SG, Oh JR, Chong A, Min JJ, Bom HS, Yoon JH, Song HC. Prognostic Significance of Metabolic Tumor Volume Measured by (18)F-FDG PET/CT in Operable Primary Breast Cancer. Nucl Med Mol Imaging 2012;46:278-285.
  18. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
  19. Edge SB, Byrd DR, Carducci MA, Compton CC, Fritz A, Greene F. AJCC cancer staging manual: Springer New York; 2010.
  20. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 2014;138:241-256.
  21. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-1167.
  22. Kitajima K, Fukushima K, Miyoshi Y, Nishimukai A, Hirota S, Igarashi Y, Katsuura T, Maruyama K, Hirota S. Association between 18F-FDG uptake and molecular subtype of breast cancer. Eur J Nucl Med Mol Imaging 2015;42:1371-1377.
  23. Kaida H, Toh U, Hayakawa M, Hattori S, Fujii T, Kurata S, Kawahara A, Hirose Y, Kage M, Ishibashi M. The relationship between 18F-FDG metabolic volumetric parameters and clinicopathological factors of breast cancer. Nucl Med Commun 2013;34:562-570.
  24. Groheux D, Majdoub M, Tixier F, Le Rest CC, Martineau A, Merlet P, Espié M, de Roquancourt A, Hindié E, Hatt M, Visvikis D. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Eur J Nucl Med Mol Imaging 2015;42:1682-1691.
  25. Robinson BD, Sica GL, Liu YF, Rohan TE, Gertler FB, Condeelis JS, Jones JG. Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res 2009;15:2433-2441.
  26. Önner H, Canaz F, Dinçer M, Işiksoy S, Sivrikoz İA, Entok E, Erkasap S. Which of the fluorine-18 fluorodeoxyglucose positron emission tomography/computerized tomography parameters are better associated with prognostic factors in breast cancer? Medicine (Baltimore) 2019;98:e15925.
  27. Ekmekcioglu O, Aliyev A, Yilmaz S, Arslan E, Kaya R, Kocael P, Erkan ME, Halac M, Sonmezoglu K. Correlation of 18F-fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma. Nucl Med Commun 2013;34:1055-1067.
  28. Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol 2008;38:250-258.
  29. Buck A, Schirrmeister H, Kühn T, Shen C, Kalker T, Kotzerke J, Dankerl A, Glatting G, Reske S, Mattfeldt T. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002;29:1317-1323.
  30. Sanli Y, Kuyumcu S, Ozkan ZG, Işik G, Karanlik H, Guzelbey B, Turkmen C, Ozel S, Yavuz E, Mudun A. Increased FDG uptake in breast cancer is associated with prognostic factors. Ann Nucl Med 2012;26:345-350.
  31. Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L, Boichot C, Cochet A, Fumoleau P, Brunotte F. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007;34:1915-1924.
  32. Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer 2007;14:260-268.
  33. Ikenaga N, Otomo N, Toyofuku A, Ueda Y, Toyoda K, Hayashi T, Nishikawa K, Tanaka M. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg 2007;73:1151-1157.
  34. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-8423.
  35. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R; Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011;12:236-244.
  36. Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res 2012;14:R83.
  37. Hatt M, Cheze-Le Rest C, Aboagye EO, Kenny LM, Rosso L, Turkheimer FE, Albarghach NM, Metges JP, Pradier O, Visvikis D. Reproducibility of 18F-FDG and 3’-deoxy-3’-18F-fluorothymidine PET tumor volume measurements. J Nucl Med 2010;51:1368-1376.
  38. Marinelli B, Espinet-Col C, Ulaner GA, McArthur HL, Gonen M, Jochelson M, Weber WA. Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. Am J Nucl Med Mol Imaging 2016;6:120-127.
Advanced Search

Article Tools

About Journal

Forms

Useful Links

Subscribe
Pubmed Central
Scopus
Latest Update: 16.04.2024
2024 © Galenos Publishing House.